Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adenosine in COVID-19 related ARDS
NCT04588441Phase 2Withdrawn
- Sponsor
- University of Florida
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
Phase 2, open-label, single-arm trial of adenosine in acute respiratory distress syndrome (ARDS), sponsored by University of Florida. Primary endpoint: Improved COVID-19 symptoms at 50 days. Planned start Dec 2023; status: withdrawn.
02
Drugs
adenosine
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04588441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04588441.